In the last trading session, the stock price of Endo International plc – Ordinary Shares (NASDAQ:ENDP) jumped more than 13% to close the day at $6.93. The gains came at a share volume of 12.14 million compared to average share volume of 7.58 million.
During Q3 2017, the U.S. Generic Pharmaceuticals division introduced vigabatrin for oral solution USP, the preliminary generic version of Sabril®, as well as sodium phenylbutyrate tablets, the initial generic equivalent of Buphenyl®. So far in 2017, Par has introduced 14 new generic offerings and has done nine submissions to regulatory authorities.
U.S. Generic Pharmaceuticals posted revenue of $497 million, a drop of 7% over third-quarter 2016, as the drop in the U.S. Generics Base business was partly offset by robust growth in Sterile Injectables. During Q3 2017, sterile Injectables revenue jumped 28% compared to Q3 2016; this jump was led mainly by VASOSTRICT® and ADRENALIN®.
The revenue of U.S. Generics Base business dropped 27% over third-quarter 2016; this drop mainly resulted from the impact on Q3 2017 related to 2017 and 2016 competitive events, previously reported product discontinuances and the sustained impact on pricing following consolidation among Endo’s trade accounts.
During Q3 2017, Endo, in association with Tim Herron, introduced Facts on Hand, an unbranded drive to increase awareness of Dupuytren’s Contracture, a growing, potentially disfiguring hand condition. The company also recently introduced numerous direct-to-consumer measures planned to raise patient awareness of XIAFLEX® as a prospective treatment alternative for Peyronie’s Disease and Dupuytren’s Contracture.
U.S. Branded Pharmaceuticals posted revenue of $234 million, a 16% drop compared to Q3 2016; this decrease was mainly attributable to generic competition unfavorably impacting the firm’s recognized products portfolio, the divestitures of BELBUCA® and STENDRA® and the drop in revenues of OPANA® ER coming from the end of product shipments by September 1, 2017.